hSulf‑1 inhibits cell proliferation and migration and promotes apoptosis by suppressing stat3 signaling 
in hepatocellular carcinoma

Ling,Liu; Feng,Ding; Jiwei,Chen; Boyong,Wang; Zhisu,Liu

doi:10.3892/ol.2014.1848

hSulf‑1 inhibits cell proliferation and migration and promotes apoptosis by suppressing stat3 signaling in hepatocellular carcinoma

Authors:
- Liu Ling
- Ding Feng
- Chen Jiwei
- Wang Boyong
- Liu Zhisu
View Affiliations

Affiliations: Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Clinical Laboratory, Wuhan Puai Hospital, Wuhan, Hubei 430033, P.R. China
Published online on: February 3, 2014 https://doi.org/10.3892/ol.2014.1848
Pages: 963-969

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human sulfatase‑1 (hSulf‑1) has been shown to desulfate cellular heparin sulfate proteoglycans and modulate several growth factors and cytokines. However, hSulf‑1 has not been previously shown to mediate the signal transducer and activator of transcription 3 (stat3) signaling pathway, which is known to regulate cell proliferation, motility and apoptosis. The present study investigated the role of hSulf‑1 in stat3 signaling in hepatocellular cancer. hSulf‑1 expression vector and stat3 small interfering RNA (siRNA) were constructed to control the expression of hSulf‑1 and stat3 in HepG2 cells. hSulf‑1 was found to inhibit the phosphorylation of stat3 and downregulate its targeted protein. MTT and Transwell chamber assays, as well as Annexin V/propidium iodide double‑staining methods, were used to examine the effects of hSulf‑1 on stat3‑mediated motility, proliferation and apoptosis in HepG2 cells. Transfection with hSulf‑1 cDNA and/or stat3 siRNA inhibited cell proliferation and motility, concurrent with G0/G1 and G2/M phase cell cycle arrest and apoptosis. Overall, the results of the current study suggested that hSulf‑1 functions as a negative regulator of proliferation and migration and as a positive regulator of apoptosis in hepatocellular carcinoma, at least partly via the downregulation of stat3 signaling.

View Figures

View References

1	el-Serag HB: Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 5:87–107. 2001. View Article : Google Scholar
2	He J, Gu D, Wu X, et al: Major causes of death among men and women in China. N Engl J Med. 353:1124–1134. 2005. View Article : Google Scholar : PubMed/NCBI
3	Lin X: Functions of heparan sulfate proteoglycans in cell signaling during development. Development. 131:6009–6021. 2004. View Article : Google Scholar : PubMed/NCBI
4	Park PW, Reizes O and Bernfield M: Cell surface heparan sulfate proteo-glycans: selective regulators of ligand-receptor encounters. J Biol Chem. 275:29923–29926. 2000. View Article : Google Scholar : PubMed/NCBI
5	Kirkpatrick CA and Selleck SB: Heparan sulfate proteoglycans at a glance. J Cell Sci. 120:1829–1832. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kikuchi A and Yamamoto H: Regulation of Wnt signalling by receptor-mediated endocytosis. J Biochem. 141:443–451. 2007. View Article : Google Scholar : PubMed/NCBI
7	Staub J, Chien J, Pan Y, et al: Epigenetic silencing of HSulf-1 in ovarian cancer: implications inchemoresistance. Oncogene. 26:4969–4978. 2007. View Article : Google Scholar : PubMed/NCBI
8	Lai J, Chien J, Staub J, et al: Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem. 278:23107–23117. 2003. View Article : Google Scholar
9	Chen Z, Fan JQ, Li J, et al: Promoter hypermethylation correlates with the HSulf-1 silencing in human breast and gastric cancer. Int J Cancer. 124:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
10	Monneret C: Histone deacetylase inhibitors. Eur J Med Chem. 40:1–13. 2005. View Article : Google Scholar
11	Pye DA, Vives RR, Turnbull JE, Hyde P and Gallagher JT: Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem. 273:22936–22942. 1998. View Article : Google Scholar
12	Lai JP, Chien J, Strome SE, et al: HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene. 23:1439–1447. 2004. View Article : Google Scholar : PubMed/NCBI
13	Lai JP, Chien JR, Moser DR, et al: hSulf-1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology. 126:231–248. 2004. View Article : Google Scholar
14	Li J, Kleeff J, Abiatari I, et al: Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer. 4:142005. View Article : Google Scholar : PubMed/NCBI
15	Dai Y, Yang Y, MacLeod V, et al: HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem. 280:40066–40073. 2005. View Article : Google Scholar : PubMed/NCBI
16	Lai JP, Sandhu DS, Shire AM and Roberts LR: The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J Gastrointest Cancer. 39:149–158. 2008. View Article : Google Scholar : PubMed/NCBI
17	Narita K, Staub J, Chien J, et al: HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res. 66:6025–6032. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ji W, Yang J, Wang D, et al: hSulf-1 gene exhibits anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers. PLoS ONE. 6:e232742011. View Article : Google Scholar : PubMed/NCBI
19	Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene. 19:2474–2788. 2000. View Article : Google Scholar : PubMed/NCBI
20	Rahaman SO and Harbor PC: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 21:8404–8413. 2002. View Article : Google Scholar
21	Iwamaru A, Szymanski S, Iwado E, et al: A novel inhibitor of the stat3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 26:2435–2444. 2007. View Article : Google Scholar : PubMed/NCBI
22	Jacoby JJ, Kalinowski A, Liu MG, et al: Cardiomyocyte restricted knockout of stat3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA. 100:12929–12934. 2003. View Article : Google Scholar
23	Kurdi M and Booz GW: Can the protective actions of JAK-stat in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling. J Cardiovasc Pharmacol. 50:126–141. 2007. View Article : Google Scholar
24	Bores P and Miller CM: Hepatocyte growth factor: a multifunctional cytokine. Lancet. 345:293–295. 1995. View Article : Google Scholar : PubMed/NCBI
25	Lee KH, Choi EY, Hyun MS, et al: Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 25:89–96. 2008. View Article : Google Scholar
26	Moore AE, Greenhough A, Roberts HR, et al: HGF/Met signaling promotes PGE2 biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis. 30:1796–1804. 2009. View Article : Google Scholar
27	Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K and Emerson CP Jr: Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem. 281:4969–4976. 2006. View Article : Google Scholar : PubMed/NCBI
28	Diez-Roux G and Ballabio A: Sulfatases and human disease. Annu Rev Genomics Hum Genet. 6:355–379. 2005. View Article : Google Scholar : PubMed/NCBI
29	Forsten-Williams K, Chu CL, Fannon M, Buczek-Thomas JA and Nugent MA: Control of growth factor networks by heparan sulfate proteoglycans. Ann Biomed Eng. 36:2134–2148. 2008. View Article : Google Scholar : PubMed/NCBI
30	Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM and Emerson CP Jr: Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science. 293:1663–1666. 2001. View Article : Google Scholar : PubMed/NCBI
31	Ornitz DM: FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays. 22:108–112. 2000. View Article : Google Scholar : PubMed/NCBI
32	Fletcher S, Turkson J and Gunning PT: Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem. 3:1159–1168. 2008. View Article : Google Scholar : PubMed/NCBI
33	Chen Z and Han ZC: STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 28:185–200. 2008. View Article : Google Scholar : PubMed/NCBI
34	Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007. View Article : Google Scholar : PubMed/NCBI
35	Yu ZY, Huang R, Xiao H, et al: Fluacrypyrim, a novel stat3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active stat3. Int J Cancer. 127:1259–1270. 2010. View Article : Google Scholar : PubMed/NCBI